Because of these recent changes in the therapeutic landscape, no vigorous data is available to inform on the selection of patients for a specific treatment for CRPC. In addition to docetaxel, which has been used for over a decade, new drugs have shown efficacy with improvements in overall survival leading to licensing for the treatment of metastatic castration-resistant prostate cancer (CRPC). The survival of patients with metastatic prostate cancer progressing on ADT (castration- resistant prostate cancer) has improved substantially. Men with localised disease can have very different treatment options, ranging from observation alone through to radical surgery, for each individual patient.įor those who have metastatic prostate cancer, the most common first line treatment option is androgen deprivation therapy (ADT). With contemporary treatment options, the overall survival for this group of patients is over 90%. Nowadays most of the patients are getting diagnosed as localized prostate cancer. In addition, it is the most common solid cancer and the most common cause of death due to cancer in European men. Prostate cancer is the most common visceral malignancy amongst men in the US. Received 27 July 2016 accepted 15 August 2016 published 18 August 2016 Which other factors can be useful are needed. The studyīeing retrospective and the low number of patients included in thisĬohort can be the main weaknesses of this study. Rate to docetaxel chemotherapy was found to be a valuable parameter. By means of overall survival, the clinical stage at the time ofĭiagnosis was the best predictive tool for our cohort. PSAĭoubling time is not a useful predictive tool for predicting response toĭocetaxel.

The most significant parameter that affects the PSA doubling time was the clinical stage at the time of diagnosis. The best PSA response rate to docetaxel chemotherapy being over or under 50%. Statistically significant prognostic parameter affecting overall survival was After the onset ofĭocetaxel, PSA response to therapy and overall survival rates were analyzed toįigure out if these parameters were related to PSA doubling time. Metastatic prostate cancer that were given at least 4 cycles of docetaxelĬhemotherapy between 20 were evaluated. Retrospectively, 70 patients who had hormone refractory To question the value of the PSA response toĬhemotherapy. Predict the patients who will benefit from docetaxel chemotherapy most, and also We tried to find out if the PSA doubling time helps us to The prognostic factors to determine this response are Start or discontinue chemotherapy for patients with castration resistant In the targeted therapy era, it is critical to know the certain points to

Psa doubling time survival rate